Business Wire

FPT and De Heus Partner to Elevate Security Operations in High-Tech Agribusiness

25.3.2024 11:06:00 EET | Business Wire | Press release

Share

Global IT corporation FPT and De Heus recently entered a strategic partnership to foster the agriculture giant's security operations.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240320729005/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

De Heus Vietnam COO Rick van der Linden (L) and FPT Software Europe CEO Tran Van Dung (R) at the signing ceremony attended by senior leaders of the Netherlands government during the economic mission to Vietnam (Photo: Business Wire)

The two firms will join forces to support De Heus’ Security Operations Center, focusing on the scope of Security Information and Event Management (SIEM). Leveraging FPT's prowess in technology and high-quality workforce, this movement will bolster De Heus’ capabilities in terms of system monitoring, security breach detection, and defense measures to effectively mitigate cyber risk and safeguard its information system and security data on a global scale.

The partnership marks a significant milestone for De Heus' digital transformation strategy amid rising cyberattack concerns in the manufacturing and agriculture industries. Both parties expect this to set a solid foundation for future collaborations in other areas like artificial intelligence, machine learning, big data, and more to further advance De Heus' and the agriculture industry's growth.

Tran Van Dung, Chief Executive Officer of FPT Software Europe, said: “While all businesses want to scale their digital transformation initiatives quickly, doing so securely is equally imperative in the face of cyber threats. Leveraging our extensive expertise and demonstrated success in deploying SIEM projects for multinational corporations globally, we stand ready to optimize De Heus' security operations.”

Rick van der Linden, Chief Operating Officer of De Heus Viet Nam, shared: “Through this partnership, FPT and De Heus are committing to leveraging our collective expertise and resources to develop robust security frameworks that will withstand the test of time. Together, we will explore innovative solutions and best practices to enhance cybersecurity measures and protect against emerging threats.”

The signing ceremony was attended by the Netherlands Minister of Infrastructure and Water Management, Mark Harbers; Minister of Agriculture, Nature, and Food Quality, Christianne van der Wal; Chair of the Confederation of Netherlands Industry and Employers, Ingrid Thijssen; and over 140 large enterprises from the Netherlands in pivotal fields of high-tech manufacturing, sustainable agriculture and food production, renewable energy, logistics, and climate adaptation and water.

Established its first office in 2008 in France, FPT has expanded its presence to 16 offices across 9 countries, serving over 70 leading businesses across Europe. Over the past decade, the tech firm has also been actively intensifying its local footprint and delivery capabilities through partnerships and acquisitions ventures, notably with the acquisition of RWE IT Slovakia, a subsidiary of European energy giant RWE in 2014, and the French IT Consulting Firm AOSIS in 2023.

About FPT Corporation

FPT Corporation (FPT) is a globally leading technology and IT services provider headquartered in Vietnam. FPT operates in three core sectors: Technology, Telecommunications, and Education. During over three decades of development, FPT has constantly provided practical and effective products to millions of people and tens of thousands of business and non-business organizations worldwide, establishing Vietnam’s position on the global tech map. Keeping up with the latest market trends and emerging technologies, FPT has developed the Made-by-FPT ecosystem of services, products, solutions, and platforms, which enables sustainable growth for organizations and businesses and offers distinctive experiences to customers. In 2023, FPT recorded a total revenue of US$2.17 billion and 73,000 employees. For more information, please visit https://fpt.com.vn/en.

About De Heus

De Heus Vietnam, a member of Royal De Heus Group, has been proud to be Vietnam's leading animal feed supplier since 2008. De Heus provides farmers comprehensive nutritional solutions to help improve livestock productivity and product quality. With a team of experienced experts and a modern factory system, De Heus is committed to providing high-quality animal feed for all types of animals, from livestock, poultry, and aquaculture to pets. De Heus' reputable brands, such as De Heus, Windmill, Koudijs, Con Cò, and Anco, have become familiar to Vietnamese farmers. De Heus always accompanies Vietnamese farmers, aiming towards developing a sustainable and prosperous agriculture.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Mai Duong (Ms.)
FPT Software
PR Manager
MCP.PR@fpt.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye